Posted by Michael Wonder on 22 Jun 2021
HIRA gives Leclaza benefits easily but delays decision on Tagrisso
22 June 2021 - Yuhan's Leclaza (lazertinib), a third-generation treatment for EGFR mutated non-small cell lung cancer, has won the health insurance benefits in just six months of obtaining the marketing license.
However, AstraZeneca’s Tagrisso (osimertinib mesylate), which was developed before Leclaza, has repeatedly failed to get the benefits in the first-line non-small cell lung cancer treatment market.
